2X10 Stock Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
ABIVAX Société Anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €11.50 |
52 Week High | €12.10 |
52 Week Low | €7.36 |
Beta | 1.46 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 54.09% |
Recent News & Updates
Recent updates
Shareholder Returns
2X10 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -3.2% | 2.0% |
1Y | n/a | -25.4% | 5.9% |
Return vs Industry: Insufficient data to determine how 2X10 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2X10 performed against the German Market.
Price Volatility
2X10 volatility | |
---|---|
2X10 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2X10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2X10's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 61 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
2X10 fundamental statistics | |
---|---|
Market cap | €882.11m |
Earnings (TTM) | -€147.74m |
Revenue (TTM) | €4.49m |
196.3x
P/S Ratio-6.0x
P/E RatioIs 2X10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2X10 income statement (TTM) | |
---|---|
Revenue | €4.49m |
Cost of Revenue | €0 |
Gross Profit | €4.49m |
Other Expenses | €152.23m |
Earnings | -€147.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 09, 2024
Earnings per share (EPS) | -2.35 |
Gross Margin | 100.00% |
Net Profit Margin | -3,288.23% |
Debt/Equity Ratio | 37.7% |
How did 2X10 perform over the long term?
See historical performance and comparison